Hantz Financial Services Inc. Has $27.61 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Hantz Financial Services Inc. increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,299 shares of the company’s stock after purchasing an additional 5,938 shares during the quarter. Hantz Financial Services Inc.’s holdings in Zoetis were worth $27,607,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new position in Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Quarry LP grew its holdings in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. Finally, LRI Investments LLC bought a new stake in Zoetis during the 1st quarter worth approximately $43,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.6 %

Shares of NYSE ZTS opened at $176.74 on Friday. The firm has a market cap of $79.74 billion, a PE ratio of 33.22, a P/E/G ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company’s fifty day simple moving average is $184.18 and its 200 day simple moving average is $180.78. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.36 earnings per share. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio is presently 32.52%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research reports. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus upped their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.